TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The investigational Lyme disease vaccine LB6V did not meet the phase III trial’s prespecified statistical success threshold in its evaluable-population analysis, despite an estimated efficacy of 73.2%. A modified intent-to-treat analysis narrowly met the threshold, but protection appeared to decline by the third season; the findings were presented at IDWeek on Oct. 27, 2026.
The investigational Lyme disease vaccine LB6V narrowly missed its prespecified success threshold in the main analysis of a phase III trial, even though its estimated efficacy was 73.2%. A modified intent-to-treat analysis produced a 74.8% estimate that just cleared the threshold, leaving the candidate’s statistical result dependent on which analysis population was used.
Among participants aged 5 and older in the evaluable population, four vaccine recipients developed Lyme disease, compared with 15 who received placebo. That yielded vaccine efficacy of 73.2%, with a 95% confidence interval of 15.8% to 93.5%. The trial’s predefined success criterion required the lower end of that interval to be above 20%, so the primary result did not meet the target.
In the modified intent-to-treat analysis, efficacy was 74.8%, with a 95% confidence interval of 21.7% to 93.9%—just above the same lower-bound threshold. Paul Auwaerter, MD, of Johns Hopkins University School of Medicine, presented the results at the IDWeek annual meeting on Oct. 27, 2026. The report does not establish that regulators have decided how to weigh the two analyses.
The placebo-controlled VALOR trial enrolled about 9,400 people at elevated risk in the United States, Canada and five European countries. Participants received four doses of LB6V or placebo, with the primary efficacy assessment beginning 28 days after dose four. The study followed participants across three Lyme disease seasons, from 2022 through 2025.
A Vaccine Option Still Uncertain
The findings matter because no Lyme disease vaccine is currently available, while Lyme disease remains a substantial public health burden in the United States. The source report says more than 80,000 cases are reported to the CDC annually and estimates that 476,000 people are treated each year. A vaccine that reduces infections could offer another prevention tool, particularly for people with frequent exposure to ticks.
But the results do not yet provide an uncomplicated efficacy case: the main analysis missed its preset benchmark, and the favorable modified analysis cleared it by a narrow margin. The observed protection also appeared to weaken over time. Those points leave questions about the strength and duration of protection, and about what additional evidence may be needed before the vaccine could become available.
Products Worth Considering
Oura Ring 4 Smart Ring – Silver – Size 8
Levoit Vital 200S-P Smart Air Purifier for Large Rooms
Hyperice Hypervolt Go 3 Percussion Massage Gun with Carry Case
As an affiliate, we earn on qualifying purchases.
How LB6V Was Tested
LB6V, previously known as VLA15, is an adjuvanted protein-subunit vaccine designed to cover six serotypes across four Borrelia species common in Europe and North America. The proposed mechanism is that vaccinated people pass antibodies to ticks as they bite; the antibodies are intended to inhibit Borrelia in the tick and prevent transmission to people.
The study participants received doses at baseline, two months, about five to nine months, and around 18 months. The trial enrolled people aged 5 and older whose occupational, home or leisure activities put them at increased risk; the median age was 47, and 97% had at least two Lyme disease risk factors. The report says the vaccine had generated immune responses and appeared safe in two earlier phase II trials.
The United States has not had a Lyme vaccine for people since LYMErix, a recombinant vaccine approved by the FDA in 1998 and withdrawn by its manufacturer in 2002 amid concerns about side effects and declining sales. That history is relevant background, but it does not determine the safety or regulatory outcome for LB6V.
“Overall, I do think this vaccine has the potential to lower the Lyme disease burden.”
— Paul Auwaerter, MD, Johns Hopkins University School of Medicine, presenting at IDWeek
Durability and Regulatory Path
The reported efficacy estimate fell from 73.2% in the second season after the four-dose series to 18.6% in the third season. The third-season confidence interval was very wide, from -220.0% to 80.4%, so that estimate is highly uncertain. Antibody levels against one measured B. burgdorferi antigen also declined, from a geometric mean titer of 1,100.3 to 35.7 between those seasons.
The available report does not say whether the sponsor will seek regulatory approval, whether regulators would accept the modified intent-to-treat result, or whether another trial or analysis will be required. It also does not establish an annual booster schedule. Safety findings require careful interpretation: adverse events were reported in 58.8% of vaccine recipients and 52.6% of placebo recipients; events prompting withdrawal were treatment-related in 0.3% and 0.1%, respectively. Newly diagnosed chronic conditions were reported at similar rates, 9.6% and 9.5%.
Further Data Will Shape Decisions
The next steps are not specified in the report. Further review of the full trial results, including the analysis populations, duration of protection and safety data, will be relevant to deciding whether LB6V advances toward regulatory review or further study. Any claim about approval timing or a booster recommendation would be premature based on the information currently reported.
Researchers may also examine whether antibody measurements can help predict protection, as Auwaerter suggested when discussing potential immunobridging studies. For now, the central result remains mixed: the primary analysis missed the trial’s preset threshold, the modified analysis narrowly met it, and the third-season estimate raises unresolved questions about how long protection lasts.
Key Questions
Did the Lyme vaccine trial succeed?
Not under the primary analysis’s preset criterion. The evaluable-population estimate was 73.2%, but its confidence interval lower bound was 15.8%, below the required level of more than 20%. A modified intent-to-treat analysis narrowly cleared that threshold.
How many participants developed Lyme disease?
In the evaluable population, four people who received LB6V and 15 who received placebo developed Lyme disease, according to the trial results presented at IDWeek.
Is LB6V available to the public?
The report describes LB6V as an investigational vaccine candidate and does not report regulatory approval or public availability.
Will people need an annual booster?
That has not been established. Auwaerter said an annual booster before Lyme season would make sense given the decline in later-season protection, but this was a researcher’s comment, not a confirmed recommendation or schedule.
Source: medpagetoday.com
